Cellnovo Delivers First Commercial Batch of Insulin Cartridges with Manufacturing Partner, Flex

PARIS--()--Regulatory News:

Cellnovo Group (Paris:CLNV) (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces that its manufacturing partner, Flex (Flex.com), the Sketch-to-Scale™ solutions provider that designs and builds Intelligent Products for a Connected World™, has completed the first commercial batch of consumables for its diabetes management system.

This development comes at the end of a period of extensive testing and validation of the mass produced Cellnovo System insulin cartridges to ensure the optimal functionality of the new mass production line at Flex’s facility in Althofen, Austria, which is expected to be operating at full capacity this summer.

At full capacity, the production line will be able to produce 600,000 insulin cartridges per year. Until then, Cellnovo and Flex will work in parallel to manufacture cartridges jointly.

Sophie Baratte, Chief Executive Officer of Cellnovo commented: “The manufacturing of the Cellnovo insulin cartridges by Flex has been our major focus since the IPO and represents a pivotal step in transforming our business and ensuring that we will be able to meet the existing high demand for our product.”

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.

For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time.

Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV

Contacts

Cellnovo
Chief Executive Officer
Sophie Baratte
investors@cellnovo.com
or
NewCap
Investor Relations
Tristan Roquet Montégon, + 33 1 44 71 00 16
or
Media Relations in France
Nicolas Merigeau, + 33 1 44 71 94 98
cellnovo@newcap.eu
or
Consilium Strategic Communications
Media Relations in United Kingdom
Amber Fennell, Chris Welsh, Laura Thornton
+44 20 3709 5700
cellnovo@consilium.com

Contacts

Cellnovo
Chief Executive Officer
Sophie Baratte
investors@cellnovo.com
or
NewCap
Investor Relations
Tristan Roquet Montégon, + 33 1 44 71 00 16
or
Media Relations in France
Nicolas Merigeau, + 33 1 44 71 94 98
cellnovo@newcap.eu
or
Consilium Strategic Communications
Media Relations in United Kingdom
Amber Fennell, Chris Welsh, Laura Thornton
+44 20 3709 5700
cellnovo@consilium.com